NFKB1 and COVID-19: Azithromycin pretreatment of COVID-19 patients can minimize LPS-induced lung bioluminescence and airway cell infiltration, lower the amount of proinflammatory cytokines in bronchoalveolar lavage, and inhibit NF-kβ nuclear translocation, according to a study by Stellari et al.33.